EISAI INC.

🇺🇸United States
Ownership
-
Employees
-
Market Cap
-
Website
Clinical Trials
Related News

Phase II Study Of E7389, Halichondrin B Analogue, In Patients With Advanced Non-Small Cell Lung Cancer, NSCLC, Who Progressed During Or After Platinum-Based Doublet Chemotherapy

First Posted Date
2005-01-10
Last Posted Date
2012-03-27
Lead Sponsor
Eisai Inc.
Target Recruit Count
106
Registration Number
NCT00100932

A Study of E7389 in Advanced/Metastatic Breast Cancer Patients

Phase 2
Completed
Conditions
Breast Neoplasms
Interventions
Drug: E7389
First Posted Date
2004-11-30
Last Posted Date
2013-04-22
Lead Sponsor
Eisai Inc.
Target Recruit Count
104
Registration Number
NCT00097721

Efficacy and Safety of Aricept in the Treatment of Severe Alzheimer's Disease

Phase 3
Completed
Conditions
Dementia
Alzheimer's Disease
First Posted Date
2004-11-10
Last Posted Date
2011-04-01
Lead Sponsor
Eisai Inc.
Target Recruit Count
229
Registration Number
NCT00096473
Locations
🇫🇷

Hôpital Broca-La Rochefoucauld, Paris, France

Evaluate the Effects of GPI 1485 on Erectile Function Following Bilateral Nerve-Sparing Prostatectomy

Phase 2
Completed
Conditions
Impotence
Prostate Cancer
First Posted Date
2004-08-30
Last Posted Date
2008-11-07
Lead Sponsor
Eisai Inc.
Target Recruit Count
240
Registration Number
NCT00090376
Locations
🇺🇸

The University of Texas MD Anderson Cancer Center, Houston, Texas, United States

🇺🇸

Henry Ford Health System, Vattikuti Institute for Urology, Detroit, Michigan, United States

🇺🇸

Johns Hopkins Hospital, Baltimore, Maryland, United States

and more 22 locations

Study to Evaluate the Efficacy, Safety, and Tolerability of E7070 in Metastatic Breast Cancer Patients

Phase 2
Completed
Conditions
Breast Neoplasms
Metastases
First Posted Date
2004-03-25
Last Posted Date
2006-10-11
Lead Sponsor
Eisai Inc.
Target Recruit Count
250
Registration Number
NCT00080197

Dosing and Safety Study of E7820 in Patients With a Malignant Solid Tumor or Lymphoma

Phase 1
Completed
Conditions
Neoplasms
Lymphoma, Malignant
First Posted Date
2004-03-05
Last Posted Date
2014-12-23
Lead Sponsor
Eisai Inc.
Target Recruit Count
37
Registration Number
NCT00078637

Irofulven Compared With Fluorouracil in Treating Patients With Pancreatic Cancer

Phase 3
Completed
Conditions
Pancreatic Cancer
Interventions
Drug: Irofulven
Drug: fluorouracil
First Posted Date
2004-01-15
Last Posted Date
2012-12-24
Lead Sponsor
Eisai Inc.
Target Recruit Count
158
Registration Number
NCT00033735
Locations
🇺🇸

MGI Pharma, Incorporated, Bloomington, Minnesota, United States

Study of E7389 Administered Once Every 3 Weeks In Patients With Advanced Solid Tumors

Phase 1
Completed
Conditions
Cancer
First Posted Date
2003-09-24
Last Posted Date
2012-04-11
Lead Sponsor
Eisai Inc.
Target Recruit Count
21
Registration Number
NCT00069277
Locations
🇺🇸

Cancer Institute Medical Group, Los Angeles, California, United States

🇺🇸

Premiere Oncology, Santa Monica, California, United States

Study of E7389 in Patients With Advanced Solid Tumors

Phase 1
Completed
Conditions
Advanced Solid Tumors
Interventions
Drug: E7389
First Posted Date
2003-09-24
Last Posted Date
2011-12-20
Lead Sponsor
Eisai Inc.
Target Recruit Count
33
Registration Number
NCT00069264

Dose-Finding Study of E7070 in Combination With Irinotecan

First Posted Date
2003-05-09
Last Posted Date
2023-06-18
Lead Sponsor
Eisai Inc.
Target Recruit Count
88
Registration Number
NCT00060567
© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy